MX339241B - Vacunas novedosas contra sub-tipos multiples de virus de influenza. - Google Patents

Vacunas novedosas contra sub-tipos multiples de virus de influenza.

Info

Publication number
MX339241B
MX339241B MX2013003382A MX2013003382A MX339241B MX 339241 B MX339241 B MX 339241B MX 2013003382 A MX2013003382 A MX 2013003382A MX 2013003382 A MX2013003382 A MX 2013003382A MX 339241 B MX339241 B MX 339241B
Authority
MX
Mexico
Prior art keywords
dna plasmid
mammal
consensus
influenza virus
immune response
Prior art date
Application number
MX2013003382A
Other languages
English (en)
Inventor
David B Weiner
Ruxandra Draghia-Akli
Jian Yan
Dominick Laddy
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX339241B publication Critical patent/MX339241B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a vacunas de ADN de plásmido capaces de generar en un mamífero una respuesta inmune contra una pluralidad de subtipos de virus de influenza, que comprenden un ADN de plásmido y un excipiente farmacéuticamente aceptable. El ADN de plásmido es capaz de expresar un antígeno de influenza consensual en una célula del mamífero en una cantidad efectiva para producir una respuesta inmune en el mamífero, en donde el antígeno de influenza consensual comprende hemaglutinina consensual (HA), neuraminidasa (NA), proteína de matriz, nucleoproteína, ectodominio-nucleo-proteína M2 (M2e-NP), o una combinación de los mismos. Preferiblemente, el antígeno de influenza consensual comprende HA, MA, M2e-NP, o una combinación de los mismos. El ADN de plásmido comprende un promotor operablemente enlazado a una secuencia de codificación que codifica el antígeno de influenza consensual. De manera adicional, un aspecto de la presente invención incluye métodos para producir una respuesta inmune contra una pluralidad de subtipos de virus de influenza en un mamífero usando las vacunas de ADN de plásmido provistas.
MX2013003382A 2007-11-12 2010-05-12 Vacunas novedosas contra sub-tipos multiples de virus de influenza. MX339241B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98728407P 2007-11-12 2007-11-12

Publications (1)

Publication Number Publication Date
MX339241B true MX339241B (es) 2016-05-18

Family

ID=40718429

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010005229A MX2010005229A (es) 2007-11-12 2008-11-12 Vacunas novedosas contra sub-tipos multiples de virus de influenza.
MX2013003382A MX339241B (es) 2007-11-12 2010-05-12 Vacunas novedosas contra sub-tipos multiples de virus de influenza.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010005229A MX2010005229A (es) 2007-11-12 2008-11-12 Vacunas novedosas contra sub-tipos multiples de virus de influenza.

Country Status (9)

Country Link
US (4) US9592285B2 (es)
EP (1) EP2217064A4 (es)
JP (5) JP5705545B2 (es)
KR (1) KR101255419B1 (es)
CN (1) CN101877965B (es)
AU (1) AU2008331673B2 (es)
CA (1) CA2705461A1 (es)
MX (2) MX2010005229A (es)
WO (1) WO2009073330A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2217064A4 (en) * 2007-11-12 2012-10-03 Univ Pennsylvania NEW VACCINES FOR FIGHT AGAINST SEVERAL SUBTYPES OF INFLUENZA VIRUSES
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
JP2013509203A (ja) * 2009-11-02 2013-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 口蹄疫ウイルス（ｆｍｄｖ）コンセンサスタンパク質、そのコード配列およびそれから生成されるワクチン
US20110184160A1 (en) * 2010-01-26 2011-07-28 Weiner David B Nucleic acid molecule encoding consensus influenza a hemagglutinin h1
US8298820B2 (en) * 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CN101892248B (zh) * 2010-04-29 2012-04-18 王世霞 禽流感h5 ha抗原的单克隆抗体
CA2811103C (en) * 2010-09-14 2020-01-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
PL2672992T3 (pl) * 2011-02-11 2020-11-02 The Trustees Of The University Of Pennsylvania Cząsteczka kwasu nukleinowego kodująca białko rdzeniowe wirusa zapalenia wątroby typu B i szczepionka je zawierająca
JP6113155B2 (ja) 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
JP6567824B2 (ja) * 2011-10-12 2019-08-28 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
US9234008B2 (en) * 2012-02-07 2016-01-12 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses
MY180109A (en) 2012-02-13 2020-11-23 Univ Pittsburgh Commonwealth Sys Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
EP2831094B1 (en) * 2012-03-30 2018-06-13 University of Pittsburgh - Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses
WO2013155205A1 (en) 2012-04-10 2013-10-17 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
JP2016505538A (ja) 2012-11-27 2016-02-25 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション Ｈ１ｎ１インフルエンザに対する計算で最適化した広い反応性を示す抗原
JP2014131987A (ja) * 2012-12-05 2014-07-17 Samsung R&D Institute Japan Co Ltd アミン誘導体、有機発光材料及びそれを用いた有機エレクトロルミネッセンス素子
WO2014165291A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Improved vaccines for human papilloma virus and methods for using the same
CN105246491B (zh) * 2013-03-15 2019-04-19 宾夕法尼亚大学理事会 针对多种登革病毒亚型的新颖疫苗
WO2014144786A1 (en) * 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of dengue virus
HK1216723A1 (zh) * 2013-03-15 2016-12-02 The Trustees Of The University Of Pennsylvania 流感核酸分子和由其製備的疫苗
CA2895806C (en) 2013-03-15 2023-02-21 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
CN103421843B (zh) * 2013-07-29 2015-12-09 中国农业科学院哈尔滨兽医研究所 编码h5n1亚型禽流感同义血凝素(ha)蛋白以及同义神经氨酸酶(na)蛋白的基因及其应用
KR101723605B1 (ko) * 2014-10-21 2017-04-07 진원생명과학 주식회사 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP3419663A1 (en) 2016-02-24 2019-01-02 Visterra, Inc. Formulations of antibody molecules to influenza virus
CN106039303A (zh) * 2016-06-20 2016-10-26 华南农业大学 一种h5亚型禽流感dna疫苗及其制备方法
JP6795468B2 (ja) * 2017-07-14 2020-12-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
EP3700561A1 (en) * 2017-10-27 2020-09-02 Statens Serum Institut A polygene influenza vaccine
US12521430B2 (en) * 2018-03-28 2026-01-13 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising neuraminidase
CA3106400A1 (en) * 2018-07-13 2020-01-16 University Of Georgia Research Foundation Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof
CN113423718A (zh) * 2019-02-08 2021-09-21 美国政府(由卫生和人类服务部的部长所代表) 基于纳米颗粒的流感病毒疫苗及其用途
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
KR102326037B1 (ko) 2019-04-18 2021-11-12 충북대학교 산학협력단 H5 인플루엔자를 치료 또는 예방하기 위한 펩타이드 및 이를 암호화하는 코돈 최적화 서열, 및 이를 이용한 백신
JP7075130B2 (ja) * 2019-10-25 2022-05-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
CN113461786B (zh) * 2020-03-30 2022-09-13 普莱柯生物工程股份有限公司 一种禽流感病毒样颗粒疫苗、及其制备方法和应用
US20250152696A1 (en) * 2021-08-13 2025-05-15 Purdue Research Foundation Methods and compositions for vaccination against heterosubtypic influenza viruses using an adenoviral vector leading to enhanced t cell response through autophagy
CN116751306A (zh) * 2023-03-17 2023-09-15 上海生物制品研究所有限责任公司 一种编码通用流感的mRNA疫苗及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
IL108449A (en) 1993-01-26 2011-09-27 Weiner David B Assemblies and methods for delivery of genetic material
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5846806A (en) * 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
DE69832706T2 (de) * 1997-08-05 2006-08-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Immunschützendes influenzaantigen und dessen verwendung zur impfung
WO1999024640A1 (en) 1997-11-12 1999-05-20 Hitachi, Ltd. Method for monitoring foreign matter of plasma treating device
JP4472250B2 (ja) * 2000-10-04 2010-06-02 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 高発現可能遺伝子
WO2003054019A2 (en) * 2001-12-21 2003-07-03 Genpat77 Pharmacogenetics Ag Therapeutic monoclonal anti-tirc7 antibodies for use in immune related and other diseases
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) * 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
CN1678345A (zh) * 2002-04-26 2005-10-05 米迪缪尼疫苗股份有限公司 制备流感病毒的多质粒系统
CA2504593C (en) * 2002-11-04 2016-08-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
CA2807534A1 (en) * 2003-02-25 2005-02-17 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
ES2748130T3 (es) * 2003-05-30 2020-03-13 Vgxi Inc Dispositivos y métodos para la producción de un biomaterial
JP5331340B2 (ja) * 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
GB0507997D0 (en) * 2005-02-01 2005-05-25 Powderject Vaccines Inc Nucleic acid constructs
CA2598884A1 (en) * 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
PT2374892T (pt) * 2005-04-29 2018-03-29 Univ Cape Town Expressão de proteínas virais em plantas
BRPI0613625A2 (pt) * 2005-07-19 2011-01-18 Dow Global Technologies Inc vacinas da gripe recombinantes
US20070116717A1 (en) 2005-08-01 2007-05-24 Shneider Alexander M Influenza vaccine compositions and methods
TWI488968B (zh) 2005-10-18 2015-06-21 Novavax Inc 功能性流行性感冒類病毒顆粒（ＶＬＰｓ）
CA2642644A1 (en) 2006-02-16 2007-09-07 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Antiviral agents and vaccines against influenza
CN1810961B (zh) * 2006-02-22 2010-05-12 中国人民解放军军事医学科学院微生物流行病研究所 一种重组流感病毒及其制备方法与应用
CA2541872A1 (en) * 2006-04-26 2007-10-26 Institut Pasteur H5 pseudotyped viruses and uses thereof
CN105063064B (zh) * 2006-07-28 2024-09-24 宾夕法尼亚大学托管会 改进的疫苗及其使用方法
CA2666501C (en) * 2006-10-17 2017-03-21 Vgx Pharmaceuticals, Inc. Electroporation devices and methods of using same for electroporation of cells in mammals
TWI403518B (zh) * 2007-01-23 2013-08-01 Academia Sinica 一種流感疫苗及其使用方法
WO2008124331A1 (en) * 2007-04-03 2008-10-16 Cytogenix, Inc. Novel sequences and dna vaccines against avian flu
EP2217064A4 (en) * 2007-11-12 2012-10-03 Univ Pennsylvania NEW VACCINES FOR FIGHT AGAINST SEVERAL SUBTYPES OF INFLUENZA VIRUSES
US9540657B2 (en) * 2012-05-25 2017-01-10 California Institute Of Technology Expression of secreted and cell-surface polypeptides

Also Published As

Publication number Publication date
AU2008331673A1 (en) 2009-06-11
JP2015120753A (ja) 2015-07-02
US20180333480A1 (en) 2018-11-22
KR101255419B1 (ko) 2013-04-17
WO2009073330A3 (en) 2010-01-07
JP2017210482A (ja) 2017-11-30
JP5705545B2 (ja) 2015-04-22
WO2009073330A2 (en) 2009-06-11
US20170165353A1 (en) 2017-06-15
MX2010005229A (es) 2010-11-05
CA2705461A1 (en) 2009-06-11
JP6195943B2 (ja) 2017-09-13
US20110305664A1 (en) 2011-12-15
EP2217064A2 (en) 2010-08-18
EP2217064A4 (en) 2012-10-03
JP2011506272A (ja) 2011-03-03
US9592285B2 (en) 2017-03-14
AU2008331673B2 (en) 2014-12-11
KR20100096164A (ko) 2010-09-01
CN101877965A (zh) 2010-11-03
JP2016052333A (ja) 2016-04-14
US8133723B2 (en) 2012-03-13
JP6549194B2 (ja) 2019-07-24
JP6047610B2 (ja) 2016-12-21
JP2013247962A (ja) 2013-12-12
CN101877965B (zh) 2014-08-20
HK1149176A1 (en) 2011-09-30
US10076565B2 (en) 2018-09-18
US20090169505A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
MX339241B (es) Vacunas novedosas contra sub-tipos multiples de virus de influenza.
Haynes Influenza virus-like particle vaccines
Brazzoli et al. Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin
Soema et al. Current and next generation influenza vaccines: Formulation and production strategies
Magini et al. Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge
Kang et al. Influenza vaccines based on virus-like particles
Isakova-Sivak et al. Influenza vaccine: Progress in a vaccine that elicits a broad immune response
Wiersma et al. Developing universal influenza vaccines: hitting the nail, not just on the head
Stachyra et al. DNA vaccines against influenza.
MX345150B (es) Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1.
MX2010007461A (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
AR077757A1 (es) Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion
WO2008014521A3 (en) Improved vaccines and methods for using the same
MY180109A (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
IN2014DN05805A (es)
Quan et al. Progress in the development of virus-like particle vaccines against respiratory viruses
WO2012082803A3 (en) Method for inducing an immune response against avian, swine, spanish, h1n1, h5n9 influenza viruses and formulations thereof
Fox et al. Extending the breadth of influenza vaccines: status and prospects for a universal vaccine
CU20120057A7 (es) Composición vacunal contra el virus del dengue, kit y plásmido
JP2010506926A5 (es)
Ullah et al. DNA Vaccines against Avian Influenza: current research and future prospects
IN2015DN03070A (es)
Singh et al. Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target
Eisenhut et al. COVID-19 vaccines and coronavirus 19 variants including alpha, delta, and omicron: present status and future directions